Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2734)	7/15/2010 1:35:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ARIA seems to have found support at the $2.57 level.<g> Today is still up 7.42% on volume > half its ADV bigcharts.marketwatch.com The stock is starting to get off from the DT coming from its May 13 H at $4.41 bigcharts.marketwatch.com Back in May ARIA entered on an license agreement with MRK regarding its ridaforolimus which provided ARIA with a $50M up-front payment and MRK will assume all further costs of ridaforolimus development. <g> This agreement with MRK was not yet reflected on the bottom line at the time of the 1stQ report.<g> The ACTAY is $6, which would be a 100% gain from present levels.<g> I still have fond memories of that day in Feb 2000 when the stock went from $12 to $40 after some report on mice trials.<g> The R/R seems favorable at present levels.<g> bigcharts.marketwatch.com Bernard